Vir Biotechnology Inc
VIR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.68B
Close$
$12.26
29.2% upside
Current Fair Value
29.2% upsideUndervalued by 29.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.68 Billion |
|---|---|
| Enterprise Value | $1.49 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.16 |
| Beta | 1.62 |
| Outstanding Shares | 147,356,811 |
Return
| Return on Equity | -54.47% |
|---|---|
| Return on Assets | -43.17% |
| Return on Invested Capital | -49.08% |
Valuation & Multiples
| P/E Ratio | -3.18 |
|---|---|
| PEG | -81.38 |
| Price to Sales | - |
| Price to Book Ratio | 1.9 |
| Enterprise Value to Revenue | 22.75 |
| Enterprise Value to EBIT | -3.19 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$55.49 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$58.23 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 92.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 100.16% |
|---|---|
| Total Invested | $238,484▼ 99.98% |
| Investors Holding | 7▼ 255.00% |
ESG Score
No data
About Vir Biotechnology Inc
327 employeesVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are desi...